Warburg effect: Sugar-tagging helps drug compounds to target human prostate cancer cells

June 11, 2020

Scientists of Far Eastern Federal University (FEFU), together with German and Russian colleagues, have developed a lead compound to fight chemotherapy-resistant prostate cancer. The original design comes out as scientists combine biologically active molecules from the chemically modified pigment of sea urchins with glucose molecules to deliver the active drug substance inward the tumor cells. A related article recently was published in Marine Drugs.

To cure prostate cancer scientists decided to capitalize on the Warburg effect, which turns as tumor cells inclination to eat lots of "sugar", i.e. consume glucose compounds more intensively comparing to the majority of normal cells.

Researchers took active molecules analogous to the molecules isolated from sea urchins pigment and "sewed" on a sugar tail to them using Sulfur linker to tie up. The resulted compound was introduced to the cell culture of prostate cancer sustainable to Docetaxel, a standard chemotherapeutic drug. The outcome was cancer cells died more efficiently.

The scientific breakthrough comes out as the result of the close cooperation of teams from Russia and Germany that includes collaborators from FEFU School of Natural Sciences (Vladivostok Russia), University Medical Center Hamburg-Eppendorf (Germany), G.B. Elyakov Pacific Institute of Bioorganic Chemistry (PIBOC FEB RAS, Vladivostok, Russia), and University of Greifswald (Germany).

The Russian-German scientific paper was recognized as a best research article of the current issue of Marine Drugs.

"In our study, we benefit from the chance to combine the ideas and experience of specialists from different countries," says one of the authors of the research, Dr. Sergey Dyshlovoy, senior researcher at the Laboratory of Biologically Active Compounds of FEFU School of Natural Science. "Firstly, we had at our disposal analogues of biologically active compounds from sea urchins which antitumor potential had been increased via chemical modification by Far Eastern colleagues from PIBOC FEB RAS. Secondly, we used the broad experience of German colleagues in the field of prostate cancer to establish and explain the mechanism that makes tumor cells more sensitive to glucose-related molecules. It turned out that prostate cancer cells have a large number of receptors responsible for the uptake of glucose and associated molecules into the cell."

The scientist went on that although new drug compound effectively targets prostate cells culture there is a good prospect it might cure other types of cancer if the outcome of the first clinical trials is positive. The majority of tumor cells consume more glucose than healthy cells of the body.

The research outcomes not only in the new compound of sea urchins molecules tagged with glucose but also in the new way of conjugating them via Sulfur, instead of Oxygen, as it used to be early. The reason for the new method of molecules connection is a looking for the drug not breaking up by enzymes in the bloodstream before it hits a tumor target. Previous experiments confirm that compounds joined via Oxygen molecules are not as stable as needed.

Fall 2020, researchers plan to start the study possible side effects of the new drug, first on mice and then on other laboratory animals. Before this, the molecule of the drug compound will be further modified to assure its even greater stability in the bloodstream. The patent will secure the rights to a new generation molecule.

Considering the time spent on laboratory and subsequent clinical trials, as well as in case of these trials' success, a new on-the-shelf drug should approach the market in the next 10 years.

Prostate cancer is the second most deadly cancer for men living in developed countries.
Original research paper: https://pubmed.ncbi.nlm.nih.gov/32403427/

Far Eastern Federal University

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.